Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Leiomyosarcoma

Leiomyosarcoma

Leiomyosarcoma: A malignant soft tissue sarcoma originating from smooth muscle cells.
It commonly arises in the uterus, retroperinoeum, or gastrointestinal tract, and can also occur in the skin and vascular system.
Leiomyosarcomas are often aggressiv and metastatic, posing significant challenges for treatment and research.
PubCompare.ai leverages AI-driven comparisons to validate and identify the best protocols, preprints, and patens for advancing leiomyosarcoma studies and improving patient outcomes.

Most cited protocols related to «Leiomyosarcoma»

1
Transcriptional Profiling of Soft Tissue Sarcomas
Cited 9 times
Adequate tumor tissue for molecular studies was selected on H&E stained sections from frozen tissue tumor blocks. Areas of viable tumor highlighted on the slides were matched and macrodissected from the cryomolds for further nucleic acid extraction. Twenty-three samples with adequate quality RNA were studied on the U133A Affymetrix platform (22,000 transcripts), as previously described [9 (link)]. The transcriptional profile was compared to the expression of a well-characterized set of 34 soft tissue sarcomas (STS), spanning the most common histologic types, including: synovial sarcoma, clear cell sarcoma, gastrointestinal stromal tumor, myxoid liposarcoma, dedifferentiated liposarcoma, leiomyosarcoma, malignant fibrous histiocytoma, and fibrosarcoma [10 (link)]. These STS samples used in our original publication [10 (link)] were initially studied on the Affymetrix U95 chip platform, and then subsequently re-analyzed on the newer chip version, U133A, using the same RNA aliquot. CEL files and normalized value in MIAME format from the SFT and STT samples analyzed on the U133A chip are publically available, at below website: http://cbio.mskcc.org/Public/SFTHierarchical clustering and differentially expressed genes were obtained using Partek® Genomics Suite™ software. The default normalization used was the Robust Multi-chip Average (RMA), Log probeset using base: 2 and ProbesetSummarization:Median Polish. The clustering was performed according to ‘Euclidean metric’ and ‘Average Linkage method’ for Rows and Columns, using a Hierarchical clustering method.
Additionally, we have imported and analyzed the cDNA array data set of 13 SFT samples from West and colleagues [11 (link)], which is publically available from the Stanford Microarray Database. Significance Analysis of Microarray (SAM) was performed on this data set as described by Tusher et al. [12 (link)]. In contrast with the Affymetrix oligonucleotide platform, the cDNA array technology is based on measuring expression between competing test and reference cDNAs. This data-set was used for comparison and validation of the differentially expressed genes obtained from our study, since it investigated a different group of patients, using a different platform and statistical software.
Hajdu M., Singer S., Maki R.G., Schwartz G.K., Keohan M.L, & Antonescu C.R. (2010). IGF2 Overexpression in Solitary Fibrous Tumors is Independent of Anatomic Location and is Related to Loss of Imprinting. The Journal of Pathology, 221(3), 300-307.
Publication 2010
cDNA Microarrays Clear Cell Sarcoma of Soft Tissue DNA, Complementary DNA Chips Fibrosarcoma Freezing Gastrointestinal Stromal Tumors Genes Leiomyosarcoma Liposarcoma, Dedifferentiated Liposarcoma, Myxoid Malignant Fibrous Histiocytoma Microarray Analysis Neoplasms Nucleic Acids Oligonucleotides Patients Sarcoma Synovial Sarcoma Tissues Transcription, Genetic
2
Uterine Sarcoma Cell Lines for BRD9 Inhibition
Cited 6 times
The leiomyosarcoma (uLMS) cell line (SK-UT1, ATCC® HTB-114TM) (ATCC, Manassas, VA, USA) was cultured and maintained in ATCC-formulated Eagle’s Minimum Essential Medium with 10% of fetal bovine serum. In addition, the uterine sarcoma cell line (MES-SA) (ATCC, Manassas, VA, USA) was cultured and maintained in McCoy’s 5A medium. The immortalized human leiomyoma cell line (HuLM) and immortalized human uterine smooth muscle (UTSM) cells were a generous gift from Professor Darlene Dixon. The HuLM and UTSM cell lines were cultured and maintained in phenol red-free, Dulbecco’s Modified Eagle Medium: Nutrient Mixture F-12. We used these cell lines covering the spectrum from normal cell line (UTSM), benign uterine tumor cell line (HuLM), and uterine malignant cell lines (uLMS) to better understand the tumor progression linking to the BRD9 dysregulation in uLMS. BRD9 inhibitor (iBRD9) TP-472 was purchased from Tocris (Cat# 6000, Minneapolis, MN, USA).
Yang Q., Bariani M.V., Falahati A., Khosh A., Lastra R.R., Siblini H., Boyer T.G, & Al-Hendy A. (2022). The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells, 11(14), 2160.
Full text: Click here
Publication 2022
Benign Neoplasm Cell Lines Disease Progression Eagle Fetal Bovine Serum Fibroid Tumor Homo sapiens Leiomyosarcoma Myocytes, Smooth Muscle Myometrium Neoplasms Nutrients Phenol Relative Energy Deficiency in Sport Sarcoma Smooth Muscles Uterus
3
Molecular Subtyping of Leiomyosarcoma
Cited 6 times
Paraffin blocks of 99 Leiomyosarcoma (LMS), 4 Myometrium, 3 Leiomyoma and 6 Undifferentiated Pleomorphic Sarcomas (UPS) from 1991 to 2012 from 9 hospitals were obtained with IRB approval and a waiver of consent due to the archival nature of the specimens. Multiple 2mm-diameter cores were re-embedded into paraffin blocks longitudinally and sectioned again to ensure the purity of tumor cells. After RNA isolation, 3SEQ libraries for next generation sequencing-based expression profiling were sequenced and analysis was performed as described previously (14 (link)–20 (link)). All gene expression profiling data used for this study have been deposited in the Gene Expression Omnibus (GEO) and are publicly accessible through GSE45510, GSE53844 and GSE54511.
After filtering data to genes with a standard deviation greater than 100, transforming the data by log2 and gene-based centering, the Consensus Clustering (R package ConsensusClusteringPlus) (21 (link)) was used to determine the number of subtypes and to assign the subtype for each LMS case. This was ran over 1000 iterations with setting “Distance – (1-Pearson correlation), a 80% sample resampling, 80% gene resampling, a maximum evaluated k of 12, and agglomerative hierarchical clustering algorithm”. Silhouette width (R package cluster) (22 ) was then calculated based on the assignment from ConsensusClusteringPlus to measure the accuracy of assignments from ConsensusClusteringPlus. Separately, RNASeq data of 82 LMS cases were downloaded from the TCGA database. To compare with 3SEQ data, the TCGA data were normalized into TPM and analyzed with ConsensusClusteringPlus and Silhouette analysis as performed for 3SEQ data. Subclass mapping (23 (link)) was performed to determine the common LMS subtypes identified in 3SEQ and TCGA RNASeq datasets.
In order to get subtype specific genes, SAMSeq (24 (link)) was performed on both datasets between each subtype and all other subtypes with a FDR of 0.05. Kaplan-Meier plots were used to compute the survival curves, and Log-rank (Mantel-Cox) test was used to determine the statistical significance of survival between groups by using GraphPad Prism5 software. Significance of contingency analysis between one subtype and the other subtypes was measured by two tail Fisher’s exact test and Chi-square test with GraphPad Prism5 software. Univariate and multivariate analysis by the Cox proportional hazard method was performed using the survival package in R. Analysis of gene ontology (GO) was done using DAVID Bioinformatics Resources version 6.7 (25 (link), 26 (link)). CSF1-signature (27 (link)) positive, and CINSARC-signature (28 (link)) positive cases were identified as those cases that coordinately highly expressed these signature genes with >0.3 correlation with the centroid as performed previously (19 (link), 27 (link), 29 (link), 30 (link)). Principal component analysis (PCA) was performed on square root transformed TPM with R package pcaMethods, ellipse contour of principal components (PC) was computed and drawn with R package car.
Guo X., Jo V.Y., Mills A.M., Zhu S.X., Lee C.H., Espinosa I., Nucci M.R., Varma S., Forgó E., Hastie T., Anderson S., Ganjoo K., Beck A.H., West R.B., Fletcher C, & van de Rijn M. (2015). Clinically relevant molecular subtypes in leiomyosarcoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 21(15), 3501-3511.
Publication 2015
CSF1 protein, human Fibroid Tumor Gene Expression Genes isolation Leiomyosarcoma Malignant Fibrous Histiocytoma Myometrium Neoplasms Paraffin Paraffin Embedding Plant Roots Tail
4
FISH Analysis of Uterine Sarcomas for NTRK Fusions
Cited 4 times
FISH was performed on interphase nuclei from FFPE tissue sections of three undifferentiated uterine sarcomas and all leiomyosarcomas with TrkA or pan-Trk expression. Custom probes using bacterial artificial chromosomes (BAC) flanking NTRK1, NTRK3, LMNA, TPR, and TPM3 genes were chosen according to the UCSC genome browser (http://genome.ucsc.edu). BAC clones were retrieved from BACPAC sources of the Children’s Hospital of Oakland Research Institute (CHORI, Oakland, CA) (http://bacpac.chori.org) (Supplementary Table 1). The DNA from individual BACs were isolated according to the manufacturer’s recommendations, labeled with nick translation, and validated on normal metaphase chromosomes. Whole tissue 5 μm tumor sections mounted on charged slides were deparaffinized, pretreated, and hybridized with denatured probes overnight, followed by post-hybridization washes and counterstaining with DAPI. Slides were examined on a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany) using Isis 5 software (Metasystems). Two hundred tumor nuclei were counted, and gene rearrangement was confirmed if >20% of tumor nuclei demonstrated break-apart signals. As the NTRK1 gene on 1q25 is located in close proximity to its gene partners (LMNA, TPR and TPM3) on 1q21-23, we also applied a two color-fusion assay which can document the fusion with more confidence, as the standard break-apart assay may not be definitive due to the small gaps detected. Thus NTRK1 telomeric portion was labeled in green, while centromeric LMNA, TPR and TPM3 were labeled in red. A come-together signal (yellow), seen in >20% of tumor nuclei, was considered a positive result 14 (link).
Chiang S., Cotzia P., Hyman D.M., Drilon A., Tap W.D., Zhang L., Hechtman J.F., Frosina D., Jungbluth A.A., Murali R., Park K.J., Soslow R.A., Oliva E., Iafrate A.J., Benayed R., Ladanyi M, & Antonescu C.R. (2018). NTRK Fusions Define a Novel Uterine Sarcoma Subtype with Features of Fibrosarcoma. The American journal of surgical pathology, 42(6), 791-798.
Publication 2018
Acid Hybridizations, Nucleic Bacterial Artificial Chromosomes Biological Assay Cell Nucleus Centromere Child Chromosomes Clone Cells DAPI Fishes Gene Rearrangement Genes Genome Interphase Leiomyosarcoma Metaphase Microscopy, Fluorescence Neoplasms Sarcoma Telomere Tissues TPM3 protein, human Uterus Vision
5
Sunitinib Pharmacokinetics in Tumor Tissue
Cited 4 times
BALB/c female mice were injected with 5 × 105 Renca RCC tumor cells and treated with sunitinib (40 mg/kg/d) and sacrificed after 1 month. Experiments were approved by the Institutional Care and Use Committee at the Johns Hopkins Medical Institutions and in accordance with the NIH Guide for the care and use of laboratory animals.
Three patients diagnosed with advanced malignancies [malignant solitary fibrous tumor, colorectal cancer (CRC), and leiomyosarcoma] were treated with sunitinib in context of a clinical trial at a dose of 37.5 to 50 mg/d for at least 4 weeks. Tumors of these patients were biopsied and in parallel plasma samples were collected. The use of these samples was in accordance with the local ethical guidelines at VU University Medical Center. For the determination of sunitinib in tissue (tumor or skin), an amount of about 10 mg of snap frozen tissue was cut, put into a vial and weighed. A total of 200 μL of water was added, the sample was snap-frozen and freeze-dried overnight. For extraction, 200 μL of ice-cold 83% acetonitrile (ACN) was added and left on ice for 1 hour. After centrifugation, 50 μL of super-natant was transferred for subsequent liquid chromatography—tandem mass spectrometry (LC/MS-MS) analysis as reported previously for plasma and cell pellet homogenates (13 ). The data are expressed in micromole to allow comparison of tissue concentrations with the IC50 values in cell culture and are based on the conversion of 1 g tissue to 1 mL liquid (14 (link)).
Gotink K.J., Broxterman H.J., Labots M., de Haas R.R., Dekker H., Honeywell R.J., Rudek M.A., Beerepoot L.V., Musters R.J., Jansen G., Griffioen A.W., Assaraf Y.G., Pili R., Peters G.J, & Verheul H.M. (2011). Lysosomal Sequestration of Sunitinib: A Novel Mechanism of Drug Resistance. Clinical cancer research : an official journal of the American Association for Cancer Research, 17(23), 7337-7346.
Publication 2011
acetonitrile Animals, Laboratory Cell Culture Techniques Cells Centrifugation Colorectal Carcinoma Common Cold Freezing Leiomyosarcoma Liquid Chromatography Malignant Neoplasms Mice, Inbred BALB C Neoplasms Patients Plasma Skin Sunitinib Tandem Mass Spectrometry Tissues Tumor, Solitary Fibrous Woman

Most recents protocols related to «Leiomyosarcoma»

1
Phase II Trial of Three Metastatic Soft Tissue Sarcoma Treatments
Statistical analysis will be performed at the JCOG Data Center. The primary analysis will be performed 6 months after the end of accrual, when collection of the primary endpoint data for all enrolled patients is expected to be complete. The treatment protocol with the best point estimate of the HR for PFS, which is the primary endpoint of this study, will be the test treatment arm in a subsequent phase III trial. However, the treatment arm for the phase III trial will be decided comprehensively if the following results are obtained, taking into consideration endpoints other than PFS. First, the PFS obtained is substantially lower than expected (insufficient results for promising therapy). Second, the overall survival results differ significantly from those of PFS. Third, the frequency of adverse events among the arms differs significantly from the expected frequency.
For the primary analysis of PFS, the respective HRs of arms A to B and A to C will be calculated using an unstratified Cox proportional-hazards model for all enrolled patients, and the treatment with the best HR will be judged to be the most promising regimen. Since this study does not make judgments based on hypothesis testing, no significance level is set a priori, and no adjustment will be made for multiplicity.
Subgroup analyses based on the factors mentioned below are to be conducted, as necessary. The factors for which subgroup analyses are planned include age group 1 (< 40/ ≥ 40 years), age group 2 (< 70/ ≥ 70 years), sex (male/female), PS (0/1 and 2), histological type (liposarcoma/leiomyosarcoma/translocation-related sarcoma/other), distant metastasis 1 [(M1 and/or N1)/other], distant metastasis 2 [M1/(N1 and M0)/other], and doxorubicin (perioperative chemotherapy/palliative chemotherapy).
Endo M., Kataoka T., Fujiwara T., Tsukushi S., Takahashi M., Kobayashi E., Yamada Y., Tanaka T., Nezu Y., Hiraga H., Wasa J., Nagano A., Nakano K., Nakayama R., Hamada T., Kawano M., Torigoe T., Sakamoto A., Asanuma K., Morii T., Machida R., Sekino Y., Fukuda H., Oda Y., Ozaki T, & Tanaka K. (2023). Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib. BMC Cancer, 23, 219.
Full text: Click here
Publication 2023
Age Groups Arm, Upper Doxorubicin Leiomyosarcoma Liposarcoma Males Neoplasm Metastasis Patients Pharmacotherapy Sarcoma Translocation, Chromosomal Treatment Protocols Woman
2
Establishing Lung Mesenchymal Cell Lines
Six primary lung mesenchymal cell lines were established from 6 individual patients (3 male and 3 female; average age, 63), fulfilling diagnostic criteria for IPF including a pathological diagnosis of usual interstitial pneumonia (1 (link)) at the time of lung transplantation. Control MPCs were derived from lung tissue (2 male and 4 female; average age, 57) obtained by video-assisted thoracoscopic surgery (VATS) biopsy or lobectomy and uninvolved from the primary disease process (adenocarcinoma, n = 1; carcinoid tumor, n = 1; synovial sarcoma, n = 1; leiomyosarcoma, n = 1; bronchiectasis, n = 1; and normal lung tissue, n = 1). Cell lines were derived from lungs, characterized as mesenchymal cells, and cultivated as previously described (70 (link)).
Yang L., Gilbertsen A., Xia H., Benyumov A., Smith K., Herrera J., Racila E., Bitterman P.B, & Henke C.A. (2023). Hypoxia enhances IPF mesenchymal progenitor cell fibrogenicity via the lactate/GPR81/HIF1α pathway. JCI Insight, 8(4), e163820.
Full text: Click here
Publication 2023
Adenocarcinoma Biopsy Bronchiectasis Carcinoid Tumor Cell Lines Diagnosis Leiomyosarcoma Lung Lung Transplantation Males Mesenchymal Stem Cells Patients Synovial Sarcoma Thoracic Surgery, Video-Assisted Tissues Usual Interstitial Pneumonia Woman
3
Gastric Cancer in Young vs Older Patients
From January 2010 to May 2018, a total of 2844 patients were diagnosed with GC at Haeundae Paik Hospital, Inje University, in Busan, Korea. Of these, 537 patients were excluded based on the following exclusion criteria: (i) patients who were diagnosed with other diseases such as gastrointestinal stromal tumor (GIST), carcinoid tumor, schwannoma, and leiomyosarcoma, and (ii) patients whose pathologic data were not available (n = 500). Among them, 88 (3.8%) and 2219 (96.2%) patients were ≤40 and >40 years of age, respectively.
To evaluate the long‐term follow‐up outcomes and compare patients younger and older than 40 years, we divided the patients into younger (≤40 years, n = 70) and older (>40 years, n = 70) age groups by propensity matching. We excluded eight patients meeting the following exclusion criteria: (i) no available clinical data or clinical records, (ii) gastric metastasis due to other primary‐originated cancer, and (iii) no pathological findings. In the propensity‐matching analysis, the covariates included gender and treatment modality. In summary, the propensity analysis included a total of 132 matched patients, including 70 younger and 62 older patients, diagnosed with GC between 2010 and 2018, who were included in further analyses of pathologic findings and outcomes (Fig. 1).
This study was conducted under the ethical guidelines of the 1975 Declaration of Helsinki and approved by the institutional review board of Haeundae Paik Hospital.
Kim Y.H., Jung Y.M., Park T.Y., Jeong S.J., Kim T.H., Lee J., Park J., Kim T.O, & Park Y.E. (2023). Comparisons of pathologic findings and outcomes of gastric cancer patients younger and older than 40: a propensity score matching study in a single center of Korea. JGH Open: An Open Access Journal of Gastroenterology and Hepatology, 7(2), 118-127.
Publication 2023
Age Groups Carcinoid Tumor Ethics Committees, Research Gastric Cancer Gastrointestinal Stromal Tumors Gender Leiomyosarcoma Neoplasm Metastasis Neurilemmoma Patients Youth
4
Surgical Strategies for Soft Tissue Sarcoma
All surgeries were performed by the multidisciplinary team for soft tissue sarcoma at Zhongshan Hospital Affiliated to Fudan University. Well differentiated liposarcoma and low-grade dedifferentiated liposarcoma are mainly local recurrences, so we implement a more aggressive surgical strategy (even if the surrounding organs of the tumor are not violated by the naked eye, they will be resected together); for high-grade dedifferentiated liposarcoma, If it is evaluated that there is the invasion of surrounding organs, complete radical resection should be attempted, and combined organ resection should also be performed; leiomyosarcoma often presents as a tumor with clear borders, and if the surrounding organs invade the adjacent units of the tumor, it should be preserved; for pleomorphic undifferentiated sarcoma, malignant peripheral nerve sheath tumor, and solitary fibrous tumor, complete resection with negative margins is enough.
Zhuang A., Chen Y., Ma L., Fang Y., Yang H., Lu W., Zhou Y., Zhang Y, & Tong H. (2023). Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma. BMC Surgery, 23, 42.
Full text: Click here
Publication 2023
Leiomyosarcoma Liposarcoma, Dedifferentiated Malignant Peripheral Nerve Sheath Tumor Neoplasms Operative Surgical Procedures Recurrence Sarcoma Surgical Margins Tumor, Solitary Fibrous Well Differentiated Liposarcoma
5
Prognostic Factors and Postoperative Complications in Retroperitoneal Sarcoma Resection
We collected the baseline characteristics that might affect the patient's prognosis such as gender, age, tumor burden, and histologic subtypes. Surgery-related indicators such as operative time, intraoperative blood loss, and the number of combined organ resections were also collected. Among them, the physical status of patients before anesthesia was assessed according to the American Society of Anesthesiologists Physical Status (ASA score) [12 (link)]. Tumor burden was the sum of the maximum diameters of all tumors in the patient. According to the 2020 World Health Organization pathological classification, the pathological types were classified as follows: (1) well-differentiated liposarcoma; (2) dedifferentiated liposarcoma; (3) leiomyosarcoma; (4) solitary fibroma; and (5) Others [13 (link)]. Meanwhile, according to the French Federation of Centers for the Fight against Cancer (FNCLCC) criteria, tumors were graded into I, II, and III [13 (link)]. Complete resection was defined as grossly negative margins, including both R0 and R1 resections. In 2017, realizing that the removal of specific organs may mean more complications, the Transatlantic RPS Working Group scored the different organs removed, as follows: Adrenal gland, aortocaval lymph nodes, appendix, gallbladder, inguinal ligament, omentum, psoas fascia, and skin are 0 points; Adnexa and/or uterus, bladder, bone, diaphragm,
distal pancreas, duodenum or duodenojejunal flexure, femoral/sciatic/obturator nerve or lumbar/sacral nerve root, iliac artery and/or aorta, iliac vein and/or IVC, kidney, left colon and/or rectum, liver, lung, parietal muscles, pericardium, posterior vaginal wall, prostate (with or without seminal vesicle), psoas muscle, right colon, small bowl, spleen, stomach, testis and/ or spermatic cord and/or vas deferens, and ureter (complete or partial resection not associated with nephrectomy) is 1 point; pancreaticoduodenectomy is 2 points [7 (link)]. According to the above scoring criteria, we scored each patient's organ resection.
Postoperative complications within 30 days were the primary endpoint of this study, and were classified according to the Clavien–Dindo Classification [14 (link)] as follows: I, abnormal conditions not requiring medical therapy or surgery, endoscopy, and radiation therapy; II, complications requiring medical therapy other than Level I complications; III, complications requiring surgery, endoscopy, or radiation therapy Complications; IV, life-threatening complications; V, postoperative death. Among them, grade III or above was defined as serious postoperative complications.
Zhuang A., Chen Y., Ma L., Fang Y., Yang H., Lu W., Zhou Y., Zhang Y, & Tong H. (2023). Development and validation of a nomogram for predicting morbidity in surgically resected primary retroperitoneal sarcoma. BMC Surgery, 23, 42.
Full text: Click here
Publication 2023
Adnexa Uteri Adrenal Glands Anesthesia Anesthesiologist Aorta Bones Colon Ductus Deferens Duodenum Endoscopy Fascia Fibroma Gallbladder Gender Groin Iliac Artery Iliac Vein Kidney Leiomyosarcoma Ligaments Liposarcoma, Dedifferentiated Liver Lumbar Region Lung Malignant Neoplasms Muscle Tissue Neoplasms Nephrectomy Nerves, Femoral Nervousness Nodes, Lymph Omentum Operative Surgical Procedures Pancreas Pancreaticoduodenectomy Patients Pericardium Physical Examination Plant Roots Postoperative Complications Prognosis Prostate Psoas Muscles Radiotherapy Rectum Respiratory Diaphragm Sacrum Seminal Vesicles Skin Spermatic Cord Spleen Stomach Surgical Blood Losses Testis Therapeutics Tumor Burden Ureter Urinary Bladder Uterus Vagina Well Differentiated Liposarcoma

Top products related to «Leiomyosarcoma»

1
Sk ut 1 by American Type Culture Collection
Sourced in United States, United Kingdom
The SK-UT-1 is a cell line derived from a uterine sarcoma. It is maintained in cell culture and can be used for research purposes.
2
Sk lms 1 by American Type Culture Collection
Sourced in United States, Sweden
The SK-LMS-1 is a cell line derived from human leiomyosarcoma, a type of soft tissue sarcoma. It is a commonly used tool in cancer research and drug development.
3
Sk lms 1 human leiomyosarcoma cells by American Type Culture Collection
Sourced in United States
The SK-LMS-1 human leiomyosarcoma cells are a cell line derived from a leiomyosarcoma, a type of soft tissue sarcoma. The cells are designed for in vitro research purposes.
4
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
5
Ht1080 human fibrosarcoma cells by American Type Culture Collection
Sourced in United States, Japan
HT1080 human fibrosarcoma cells are a well-characterized cell line derived from a fibrosarcoma tumor. These cells are adherent and have a fibroblast-like morphology. They are commonly used in research applications to study cellular processes and signaling pathways.
6
Ht1080 by American Type Culture Collection
Sourced in United States, United Kingdom, Germany
The HT1080 is a laboratory instrument designed for cell culture applications. It is a fibroblast-like cell line derived from a human fibrosarcoma. The HT1080 cell line is commonly used in research and testing.
7
Sw872 by American Type Culture Collection
Sourced in United States, Germany
The SW872 is a laboratory centrifuge designed for high-speed separation of biological samples. It features a maximum speed of 22,000 RPM and a maximum relative centrifugal force (RCF) of 60,000 x g. The SW872 is capable of handling a variety of sample volumes and tube sizes to accommodate diverse research and testing needs.
8
Mes sa by American Type Culture Collection
Sourced in United States, Japan, Germany
The MES-SA is a laboratory equipment product that serves as a mechanical cell shaker. It is designed to agitate and mix cell cultures or other liquid samples in a controlled and consistent manner. The core function of the MES-SA is to provide gentle, orbital mixing to facilitate cellular growth and suspension.
9
Agilent 244k by Agilent Technologies
The Agilent 244K is a high-performance liquid chromatography (HPLC) system designed for analytical and preparative applications. It features a dual-piston pump capable of delivering precise and stable flow rates, and a versatile sample injection system. The system is designed to provide reliable and reproducible results for a wide range of chromatographic separations.
10
Doxorubicin by Teva Pharmaceuticals
Sourced in Hungary, Israel
Doxorubicin is a type of lab equipment used in pharmaceutical research and development. It is a cytotoxic anthracycline drug that is used as an anti-cancer agent. Doxorubicin inhibits the growth and proliferation of cancer cells by interfering with the enzymes involved in DNA replication and transcription.

More about "Leiomyosarcoma"

Leiomyosarcoma (LMS) is a rare and aggressive type of soft tissue sarcoma that originates from smooth muscle cells.
It commonly arises in the uterus, retroperitoneum, or gastrointestinal tract, but can also occur in the skin, blood vessels, and other areas of the body.
These tumors are often metastatic, posing significant challenges for treatment and research.
Researchers studying leiomyosarcoma frequently use cell lines such as SK-UT-1 and SK-LMS-1, which are derived from human leiomyosarcoma tumors.
These cell lines, along with HT1080 human fibrosarcoma cells, are valuable tools for understanding the biology and testing potential therapies for this disease.
To culture these cell lines, researchers often use fetal bovine serum (FBS) as a nutrient supplement.
Additionally, the Agilent 244K microarray platform has been used to analyze gene expression profiles in leiomyosarcoma samples, providing insights into the molecular mechanisms driving this cancer.
One common treatment for leiomyosarcoma is the chemotherapeutic agent doxorubicin, which can be effective but also carries significant side effects.
Ongoing research aims to identify more targeted and effective therapies, such as those based on the MES-SA cell line, to improve outcomes for patients with this challenging disease.
By leveraging AI-driven comparisons of protocols, preprints, and patents, the PubCompare.ai platform can help researchers validate and identify the best approaches for advancing leiomyosarcoma studies and improving patient care.